Literature DB >> 14768047

Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms.

Vittorio Francavilla1, Daniele Accapezzato, Marietta De Salvo, Pisana Rawson, Olivia Cosimi, Martin Lipp, Antonella Cerino, Agostino Cividini, Mario U Mondelli, Vincenzo Barnaba.   

Abstract

Hallmark of acute hepatitis C virus (HCV) infection is a severe virus-specific effector CD8(+) T cell dysfunction that seems to be a critical factor in preventing the resolution of infection and in favoring the onset of chronic liver immunopathology. We suggest that this dysfunction is critical in the establishment of HCV persistence, unless it is compensated by multispecific responses, as found in individuals resolving infection. Analyses on purified populations indicate that central memory HCV-specific CCR7(+)/CD8(+) T cells efficiently proliferate and differentiate in vitro, although the large population of memory effector CCR7(-) cells found in the peripheral blood of acutely infected patients display poor effector functions ex vivo (semi-effectors). However, we report strong evidence in support of IL-2 being capable of pushing semi-effector CTL to complete their effector cell program. Therefore, IL-2 deficiency during T cell activation may be responsible for the dichotomy between memory CTL expansion and incomplete effector differentiation shown in patients with acute HCV infection. These data are consistent with the possible therapeutic treatment with IL-2 to rebuild the effector T cell pool in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14768047     DOI: 10.1002/eji.200324539

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

Review 3.  Hepatitis C virus infection--pathobiology and implications for new therapeutic options.

Authors:  Gary L Davis; Kris Krawczynski; Gyongyi Szabo
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

Review 4.  Treatment failure in hepatitis C: mechanisms of non-response.

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Hepatol       Date:  2008-12-03       Impact factor: 25.083

Review 5.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

7.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

Authors:  Debora Franceschini; Marino Paroli; Vittorio Francavilla; Melissa Videtta; Stefania Morrone; Giancarlo Labbadia; Antonella Cerino; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

Review 9.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

10.  Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.

Authors:  Jacqueline K Flynn; Gregory J Dore; Margaret Hellard; Barbara Yeung; William D Rawlinson; Peter A White; John M Kaldor; Andrew R Lloyd; Rosemary A Ffrench
Journal:  J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.